Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667336 | 0.80 | OPRM1 (0.46) | KDM1AOPRM1OPRD1OPRK1TMEM97 | |
| SCHEMBL4700010 | 0.78 | KMT2A (0.37) | KMT2AKDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4975911 | 0.75 | DPP4 (0.40) | KMT2ASRD5A1KDM1APARP1PARP10 | |
| SCHEMBL24336229 | 0.70 | ADRA2A (0.37) | KDM1ASLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL4886864 | 0.70 | GRM5 (0.43) | KMT2ASRD5A1MEN1 | |
| SCHEMBL4899718 | 0.67 | SIGMAR1 (0.39) | OPRD1 | |
| SCHEMBL20030625 | 0.67 | SRD5A1 (0.32) | KMT2ASRD5A1KDM1ASLC6A4SLC6A3 | |
| SCHEMBL21119087 | 0.66 | AKR1B1 (0.32) | SRD5A1KDM1AMEN1HTR2AHTR2C | |
| SCHEMBL18022626 | 0.66 | SRD5A1 (0.36) | KMT2ASRD5A1KDM1ASLC6A2SLC6A4 | |
| SCHEMBL4977596 | 0.65 | KDM1A (0.40) | KMT2AKDM1APARP1PARP10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-28 | — | — | US | disclosed |
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| EP-1896479-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1893610-A2 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006134486-A2 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134485-A1 | ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | OPRL1, OPRD1, OGFRL1 | KMT2A 1091/4885SRD5A1 729/4885KDM1A 619/4885 |
| US-20080207665-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidinopropanoic Acid Compounds as Orl-1-Receptor Antagonists | OPRL1, OGFRL1, OPRD1 | KMT2A 1603/4885SRD5A1 449/4885KDM1A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.